MedTrace Logo

Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-28

Study results available
· View outcomes & findings →

Summary

Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.

Conditions

  • Macular Degeneration

Interventions

DRUG

ranibizumab

0.5 mg. given as an intraocular injection

DRUG

verteporfin

Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Texas Retina Associates

    lead OTHER

Principal Investigators

  • David Callanan, MD · Texas Retina Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00527475 on ClinicalTrials.gov